2025-12-21 - Analysis Report
Okay, let's break down the analysis of TG Therapeutics Inc. (TGTX).

**1. Return Rate Comparison (vs. S&P 500 - VOO)**

*   **Company Overview:** TG Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 72.09%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:** -28.8 (Relative Divergence: 17.8)

**Analysis:**

*   TGTX has underperformed the S&P 500 over the period examined. The divergence of -28.8 indicates that TGTX's cumulative return is lagging behind the S&P 500 by that percentage point.
*   The relative divergence of 17.8 suggests that the current divergence is closer to the *minimum* divergence seen historically between TGTX and VOO.
*   The Alpha/Beta analysis shows a volatile picture. While some periods (2018-2020, 2019-2021) saw very high CAGRs and positive Alpha (outperforming the market), other periods (2020-2022, 2021-2023) saw significant losses and negative Alpha. The Beta values are generally low, indicating the stock has not been significantly correlated with the market. The company size is relatively small, ranging from 0.7B to 8.3B during 2015-2025.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** \$30.98
*   **Previous Close:** \$29.93
*   **Change:** +3.51%
*   **5-day SMA:** \$30.85
*   **20-day SMA:** \$31.41
*   **60-day SMA:** \$33.05

**Analysis:**

*   The price closed higher than its 5-day SMA.
*   The current price is below the 20-day and 60-day SMAs, which might suggest a downward trend in the short to medium term, although the recent price increase is positive.

**3. Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 51.81
*   **PPO:** 0.0432
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (32 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** 0.8 (+) - indicates a short-term upward trend.
*   **Expected Return:** -127.3%

**Analysis:**

*   The MRI of 0.7 suggests a "Medium Investment" recommendation.
*   An RSI of 51.81 is neutral (neither overbought nor oversold).
*   The PPO (Percentage Price Oscillator) is close to zero, suggesting the 26-day and 12-day EMAs are near each other.
*   The hybrid signal is recommending a strong buy.
*   The recent increase in relative divergence (0.8) aligns with the recent price increase.
*   The *very* negative expected return (-127.3%) is a major red flag. This suggests that, based on the model used, TG Therapeutics is expected to significantly underperform the S&P 500 in the long term.

**4. Recent News & Significant Events**

*   **Earnings Caveat (Nov 3):** An article mentions a caveat in earnings that caused the stock to decline.
*   **Financials Look Strong (Oct 31):** An article suggesting that strong financials might justify a shareholder's leap.
*   **Options Market Predicting a Spike (Dec 19):**  Two articles discuss the options market indicating a potential price increase.
*   **Q3 Earnings Positives, Competitor Progress (Nov 17):** An article noting positive Q3 earnings, but also highlighting the progress of competitors.
*   **Fireside Chat (Nov 28):** TG Therapeutics scheduled a fireside chat.

**Analysis:**

*   The news is mixed. There are articles suggesting potential upside (options market, strong financials), but also cautionary notes regarding earnings caveats and competitor progress. The scheduled fireside chat could be a catalyst for information release.

**4-2. Analyst Opinions:**

*   **Consensus:**  No explicit rating key provided, so can't interpret the "-" symbol.
*   **Opinions:** 7 analysts covering the stock.
*   **Target Price:** Average target of \$44.29, with a high of \$60 and a low of \$13.
*   **Recent Rating Changes:** No specific rating changes provided.

**Analysis:**

*   Analyst coverage is present, with 7 opinions. The average target price of $44.29 suggests a potential upside from the current price of \$30.98. However, the wide range between the high and low target prices (\$60 vs \$13) indicates significant disagreement among analysts regarding the stock's future performance.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
| ---------- | ---- | -------- |
| 2025-11-05 | 2.69 | 0.16 B\$ |
| 2025-08-08 | 0.19 | 0.14 B\$ |
| 2025-05-09 | 0.03 | 0.12 B\$ |
| 2024-11-07 | 0.03 | 0.08 B\$ |
| 2025-11-05 | 0.03 | 0.08 B\$ |

**Analysis:**

*   The most recent EPS (2025-11-05) is significantly higher than previous quarters, this could be the 'earnings caveat' referenced earlier.
*   Revenue has been trending upward.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | --------------- |
| 2025-09-30   | \$0.16B   | 82.63%         |
| 2025-06-30   | \$0.14B   | 86.58%         |
| 2025-03-31   | \$0.12B   | 87.14%         |
| 2024-12-31   | \$0.11B   | 85.77%         |
| 2024-09-30   | \$0.08B   | 88.86%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-09-30   | \$0.61B   | 64.37%   |
| 2025-06-30   | \$0.28B   | 10.20%   |
| 2025-03-31   | \$0.24B   | 2.13%    |
| 2024-12-31   | \$0.22B   | 10.49%   |
| 2024-09-30   | \$0.19B   | 2.02%    |

**Analysis:**

*   Revenue is growing steadily.
*   Profit margins are exceptionally high.
*   Equity has increased significantly, especially in the most recent quarter.
*   ROE is very volatile, spiking up in the most recent quarter.

**7. Comprehensive Analysis (Summary)**

TG Therapeutics (TGTX) presents a mixed investment picture:

*   **Negative Factors:**
    *   Underperformance compared to the S&P 500.
    *   Volatile historical performance (Alpha/Beta analysis).
    *   Extremely negative expected return (-127.3%).
    *   Conflicting news headlines: one suggesting an earnings caveat led to a stock decline.

*   **Positive Factors:**
    *   Recent positive price momentum and short-term upward trend in relative divergence.
    *   Analyst target prices suggest potential upside (though with wide disagreement).
    *   Growing revenue and high profit margins.
    *   Significantly high EPS (2025-11-05)
    *   Increase in Equity

*   **Neutral Factors:**
    *   Neutral RSI.
    *   Options market suggesting a potential spike.
    *   The MRI indicates a 'Medium Investment' recommendation.

**Conclusion:**

TGTX appears to be a high-risk, high-reward investment. The extremely negative expected return is a major concern and warrants careful consideration. However, the positive aspects (recent price momentum, growing revenue, high profit margins) might attract investors with a higher risk tolerance. It's crucial to delve deeper into the "earnings caveat" mentioned in the news, understand the reason for the volatile ROE, and assess the company's competitive landscape. The upcoming fireside chat could provide valuable insights. **This is NOT a recommendation to buy or sell.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.